Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research


Proprietary MiDROPS™ technology is also available to formulate small lipohilic molecules for topical instillation (eyedrop).  This patented technology platform can deliver test agents to both the anterior and posterior segments of the eye.



EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

EyeCRO Receives Full Accreditation from AAALAC International for its Research Facilities

"EyeCRO LLC has been awarded full accreditation from AAALAC International for their facility in … Read More

Once-daily MiDROPS™ are superior to other Cyclosporine drops dosed 2x/day and provide faster therapeutic benefit to patients

"Ophthalmic distribution studies indicate significantly increased drug concentration with … Read More

EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease

Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 EyeCRO and MPI Research, … Read More

More News

Monday, March 18th, 2019 at 10:42am
We are proud to be partners with @OCAST in our continued success! Their initial funding helped solidify key elements driving our business growth. https://t.co/OD6Ybo7tJl
EyeCRO photo
Congratulations to EyeCRO on being awarded full accreditation from AAALAC International for its vision research facility in Oklahoma City. https://t.co/Rgzsk6NnJw #ResearchMatters @EyeCRO https://t.co/Q34nTHuPEt
Preclinical Ophthalmic Contract Research